For finished drug products, the sampling procedure should take account of the official and non-official tests required for the individual dosage form (e.g. GMP News 6 August 2008 . FDA will use single normal sampling for lots of 1,200 gloves or less and multiple normal sampling for all larger lots. FDA regulates the sale of medical device products in the U.S. and monitors the safety of all regulated medical products. (a) The establishment of any specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms required by this subpart, including any change in such specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms, shall be drafted by the appropriate organizational unit and reviewed and approved by the quality control unit. (a) To assure batch uniformity and integrity of drug products, written procedures shall be established and followed that describe the in-process controls, and tests, or examinations to be conducted on appropriate samples of in-process materials of each batch. 29, 1983, as amended at 60 FR 4091, Jan. 20, 1995] tablets or parenteral preparations). These activities shall be documented. Non-official tests could include testing for adulteration and counterfeiting. The choice of a sampling … However it does specify general requirements with regard to sampling and personnel which have relevance as guiding Guide, items 6.11. to 6.14. (2) The method of sampling, including the number, volume, and size of articles to be tested; (3) Written specifications for the acceptance or rejection of each lot; and (4) A statement of any other function critical to the particular sterility test method to … This annex gives additional guidance on the sampling of starting and packaging materials.” As the main content of the Annex is not concerned with finished drug product it is not summarised here. On June 8, 2020, the Food and Drug Administration (FDA or Agency) issued temporary guidance to address concerns related to distribution of drug samples during the COVID-19 public health emergency. These guidelines should be useful when surveying the national mar-kets for the quality of drug products in accordance with national drug quality surveillance programmes for marketed products, whether reg-istered for sale or compounded in pharmacies. § 211.110 Sampling and testing of in-process materials and drug products. Each manufacturer shall establish and maintain procedures to ensure that sampling methods are adequate for their intended use and to ensure that when changes occur the sampling plans are reviewed. § 203.32 - Drug sample storage and handling requirements. Current Interpretation of the FDA Requirements on Sampling In October 2007, in the "Questions and Answers on Current Good Manufacturing Practices", the successor document to the human Drug CGMP Notes, there was an interesting question on sampling and on identity testing of starting materials (active pharmaceutical ingredients (APIs) and excipients): § 203.33 - Drug sample forms. 1 Under an exercise of enforcement discretion, the FDA has declared it will not enforce certain requirements of the Prescription Drug Marketing Act of 1987 (PDMA) and its implementing … [48 FR 13025, Mar. (3) For an OTC drug product that is exempt for bearing an expiration date under § 211.137, the reserve sample must be retained for 3 years after the lot or batch of drug product is distributed. (b) Sampling plans, when used, shall be written and based on a valid statistical rationale. § 203.34 - Policies and procedures; administrative systems. FDA will use general inspection level II in determining the sample size for any lot size.